Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Gross Profit (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed Gross Profit for 10 consecutive years, with $29.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit fell 3.55% year-over-year to $29.5 million, compared with a TTM value of $113.6 million through Dec 2025, up 7.5%, and an annual FY2025 reading of $113.6 million, up 7.5% over the prior year.
  • Gross Profit was $29.5 million for Q4 2025 at Heron Therapeutics, up from $26.3 million in the prior quarter.
  • Across five years, Gross Profit topped out at $30.6 million in Q4 2024 and bottomed at -$15.7 million in Q3 2021.
  • Average Gross Profit over 5 years is $16.1 million, with a median of $13.6 million recorded in 2021.
  • The sharpest move saw Gross Profit crashed 222.96% in 2021, then skyrocketed 419.75% in 2022.
  • Year by year, Gross Profit stood at -$3.8 million in 2021, then surged by 419.75% to $12.3 million in 2022, then skyrocketed by 98.71% to $24.3 million in 2023, then increased by 25.48% to $30.6 million in 2024, then dropped by 3.55% to $29.5 million in 2025.
  • Business Quant data shows Gross Profit for HRTX at $29.5 million in Q4 2025, $26.3 million in Q3 2025, and $27.3 million in Q2 2025.